Take a look at our previous reports:

15. Property, Plant and Equipment

Fully owned

(thousands of €)

Land, building and building improve­ments

Installation &
machinery

Furniture, fixtures & vehicles

Other 
tangible
assets

Total

Acquisition value

 

 

 

 

 

 

 

 

 

 

 

On January 1, 2024

90,705

39,678

9,353

6,770

146,507

Additions

7,292

9,595

118

298

17,303

Sales and disposals

(6,554)

(663)

(2,460)

 

(9,677)

Reclassifications

4,687

470

466

(5,623)

Reclassifications to assets in disposal group classified as held for sale

(10,200)

 

 

(915)

(11,115)

Translation differences

84

204

(15)

 

273

On December 31, 2024

86,014

49,284

7,462

530

143,291

Additions

1,622

10,788

18

 

12,428

Sales and disposals

(758)

(29,284)

(1,495)

 

(31,537)

Reclassifications

(1,283)

1,813

 

(530)

Translation differences

(606)

(667)

(1)

 

(1,274)

On December 31, 2025

84,989

31,934

5,984

122,908

 

 

 

 

 

 

Depreciation and impairment

 

 

 

 

 

 

 

 

 

 

 

On January 1, 2024

11,218

19,178

4,891

35,287

Depreciations

5,284

4,787

1,005

 

11,076

Impairment

1,068

17

158

 

1,243

Sales and disposals

(6,554)

(663)

(2,460)

 

(9,677)

Translation differences

(68)

39

(8)

 

(37)

On December 31, 2024

10,948

23,358

3,586

37,892

Depreciations

4,021

5,562

768

 

10,351

Impairment

4,155

27,900

661

 

32,716

Sales and disposals

(758)

(27,205)

(1,485)

 

(29,448)

Translation differences

(203)

(345)

(1)

 

(549)

On December 31, 2025

18,163

29,270

3,530

50,962

 

 

 

 

 

 

Carrying amount

 

 

 

 

 

 

 

 

 

 

 

On December 31, 2024

75,066

25,926

3,876

530

105,399

On December 31, 2025

66,826

2,664

2,455

71,946

As a result of the announced wind-down of our cell therapy activities and the planned closure of sites, we recorded in 2025 an impairment on lab equipment of €19.4 million, on leasehold improvements of €3.6 million and on other assets of €0.1 million. We additionally recorded an impairment of €9.6 million on the assets related to the small molecules business.

As we signed a share purchase agreement for the construction project in Mechelen (Belgium) in December 2024, we reclassified the land and other tangible assets of Galapagos Real Estate Belgium BV to assets in disposal group classified as held for sale at December 31, 2024.

Right-of-use

(thousands of €)

Land &
building

Installation &
machinery

Furniture,
fixtures &
vehicles

Total

Acquisition value

 

 

 

 

 

 

 

 

 

On January 1, 2024

23,174

251

7,652

31,078

Additions

4,287

1,657

2,879

8,823

Sales and disposals

(2,989)

(250)

(4,114)

(7,353)

Translation differences

113

 

 

113

On December 31, 2024

24,585

1,658

6,417

32,661

Additions

2,181

 

526

2,707

Sales and disposals

(12,023)

(459)

(4,962)

(17,444)

Translation differences

(549)

 

 

(549)

On December 31, 2025

14,194

1,199

1,981

17,375

 

 

 

 

 

Depreciation and impairment

 

 

 

 

 

 

 

 

 

On January 1, 2024

11,279

223

4,473

15,976

Depreciations

2,848

118

1,592

4,558

Sales and disposals

(1,920)

(250)

(3,200)

(5,370)

Translation differences

(3)

 

 

(3)

On December 31, 2024

12,204

91

2,865

15,161

Depreciations

2,185

381

1,351

3,917

Impairment

3,655

 

 

3,655

Sales and disposals

(10,811)

(145)

(2,890)

(13,846)

Translation differences

(229)

 

 

(229)

On December 31, 2025

7,004

327

1,326

8,658

 

 

 

 

 

Carrying amount

 

 

 

 

 

 

 

 

 

On December 31, 2024

12,381

1,567

3,552

17,499

On December 31, 2025

7,190

872

655

8,717

Carrying amount

 

December 31

(thousands of €)

2025

2024

Property, plant and equipment fully owned

71,946

105,399

Right-of-use

8,717

17,499

Total property, plant and equipment

80,663

122,898

We recorded in 2025 an impairment on the right of use assets related to the leased buildings in Princeton and Pittsburgh (U.S.), as these sites will be closed as a result of the wind-down. The sales and disposals of 2025 and 2024 mainly relate to the disposal of leased cars.

We refer to note 26 “Lease liabilities” for a detail of the lease liabilities related to these right-of-use assets.

There are no pledged items of property, plant and equipment. There are also no restrictions in use on any items of property, plant and equipment.

Cell therapy
Cell therapy aims to treat diseases by restoring or altering certain sets of cells or by using cells to carry a therapy through the body. With cell therapy, cells are cultivated or modified outside the body before being injected into the patient. The cells may originate from the patient (autologous cells) or a donor (allogeneic cells)